Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simeprevir with PegIFN and Ribavirin in Japanese Genotype 1 HCV Patients
NCT01366638Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2011
- Primary completion
- Nov 2012
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label trial of simeprevir in hepatitis C (HCV) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Sustained Virologic Response 12 Weeks After End of Treatment at 60 weeks, Sustained Virologic Response 24 Weeks After End of Treatment at 72 weeks and 8 more. Started May 2011; status: completed.
02
Drugs
simeprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01366638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01366638.